Lawrence Lum

Summary

Affiliation: Roger Williams Medical Center
Country: USA

Publications

  1. ncbi request reprint Retargeting T cells and immune effector cells with bispecific antibodies
    Lawrence G Lum
    Immunotherapy Program, Adele R Deof Cancer Center, Roger Williams Hospital, Providence, RI 02908, USA
    Cancer Chemother Biol Response Modif 22:273-91. 2005
  2. ncbi request reprint Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
    Ursula Reusch
    Cancer Immunotherapy Program, Adele R Decof Cancer Center, Providence, Rhode Island, USA
    Clin Cancer Res 12:183-90. 2006
  3. ncbi request reprint Antibody targeting of stem cells to infarcted myocardium
    Randall J Lee
    Department of Medicine and Cardiovascular Research Institute, University of California San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143 1354, USA
    Stem Cells 25:712-7. 2007
  4. ncbi request reprint Virtual reality of stem cell transplantation to repair injured myocardium
    Lawrence G Lum
    Immunotherapy and Blood and Marrow Stem Cell Transplantation Programs, Adele R Decof Cancer Center, Department of Medicine, Brown University School of Medicine, USA
    J Cell Biochem 95:869-74. 2005
  5. ncbi request reprint Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells
    Lawrence G Lum
    Immunotherapy and Blood and Stem Cell Transplantation Programs, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Clin Breast Cancer 4:212-7. 2003
  6. ncbi request reprint Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells
    Lawrence G Lum
    Adele R Decof Cancer Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Med Health R I 86:247-8. 2003
  7. ncbi request reprint Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium
    Lawrence G Lum
    Immunotherapy Program, Adele R Decof Cancer Center, Providence, RI 02908, USA
    Blood Cells Mol Dis 32:82-7. 2004
  8. ncbi request reprint The new face of bispecific antibodies: targeting cancer and much more
    Lawrence G Lum
    Immunotherapy Program, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Exp Hematol 34:1-6. 2006
  9. ncbi request reprint Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation
    Ryan C Grabert
    Immunotherapy and Blood and Stem Cell Transplant Programs, Adele R Decof Cancer Center and Division of Hematology Oncology, Department of Medicine, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Clin Cancer Res 12:569-76. 2006
  10. ncbi request reprint Tissue engineering and stem cell therapy for myocardial repair
    Yiping Gu
    University of California Berkeley and San Francisco Joint Bioengineering Graduate Group, USA
    Front Biosci 12:5157-65. 2007

Research Grants

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Retargeting T cells and immune effector cells with bispecific antibodies
    Lawrence G Lum
    Immunotherapy Program, Adele R Deof Cancer Center, Roger Williams Hospital, Providence, RI 02908, USA
    Cancer Chemother Biol Response Modif 22:273-91. 2005
    ....
  2. ncbi request reprint Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
    Ursula Reusch
    Cancer Immunotherapy Program, Adele R Decof Cancer Center, Providence, Rhode Island, USA
    Clin Cancer Res 12:183-90. 2006
    ..This study combines EGFR-targeting with the non-MHC-restricted cytotoxicity of anti-CD3 activated T cells (ATC) to enhance receptor-directed cytotoxicity...
  3. ncbi request reprint Antibody targeting of stem cells to infarcted myocardium
    Randall J Lee
    Department of Medicine and Cardiovascular Research Institute, University of California San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143 1354, USA
    Stem Cells 25:712-7. 2007
    ..01). Bispecific antibody targeting offers a unique means to improve the delivery of stem cells to facilitate organ repair and a tool to study stem cell biology...
  4. ncbi request reprint Virtual reality of stem cell transplantation to repair injured myocardium
    Lawrence G Lum
    Immunotherapy and Blood and Marrow Stem Cell Transplantation Programs, Adele R Decof Cancer Center, Department of Medicine, Brown University School of Medicine, USA
    J Cell Biochem 95:869-74. 2005
    ....
  5. ncbi request reprint Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells
    Lawrence G Lum
    Immunotherapy and Blood and Stem Cell Transplantation Programs, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Clin Breast Cancer 4:212-7. 2003
  6. ncbi request reprint Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells
    Lawrence G Lum
    Adele R Decof Cancer Center, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Med Health R I 86:247-8. 2003
  7. ncbi request reprint Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium
    Lawrence G Lum
    Immunotherapy Program, Adele R Decof Cancer Center, Providence, RI 02908, USA
    Blood Cells Mol Dis 32:82-7. 2004
    ..These results suggest that stem cells retargeted with BiAb can be directly injected and retained by injured myocardium or targeted to injured myocardial tissues for tissue regeneration...
  8. ncbi request reprint The new face of bispecific antibodies: targeting cancer and much more
    Lawrence G Lum
    Immunotherapy Program, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Exp Hematol 34:1-6. 2006
    ....
  9. ncbi request reprint Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation
    Ryan C Grabert
    Immunotherapy and Blood and Stem Cell Transplant Programs, Adele R Decof Cancer Center and Division of Hematology Oncology, Department of Medicine, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Clin Cancer Res 12:569-76. 2006
    ..Studies reported herein were designed to characterize bispecific antibody-armed ATC functions during multiple rounds of targeted cell stimulation...
  10. ncbi request reprint Tissue engineering and stem cell therapy for myocardial repair
    Yiping Gu
    University of California Berkeley and San Francisco Joint Bioengineering Graduate Group, USA
    Front Biosci 12:5157-65. 2007
    ..Here, we review the current progress in cardiac tissue repair and engineering; and discuss the new emerging technologies...
  11. pmc The new stem cell biology
    Peter J Quesenberry
    Department of Research, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Trans Am Clin Climatol Assoc 113:182-206; discussion 206-7. 2002
    ..These observations, along with progress in using low dose treatments and tolerization approaches, suggest many new therapeutic strategies involving stem cells and the creation of a new medical specialty; stemology...
  12. ncbi request reprint Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas
    Hillary E Lum
    Clinical Sciences Center, University of Wisconsin Medical School, Madison, WI 53792, USA
    Anticancer Res 25:43-52. 2005
    ....
  13. ncbi request reprint T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
    Jonathan M Gall
    Cancer Immunotherapy Laboratory and Blood and Bone Marrow Transplant Programs, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Exp Hematol 33:452-9. 2005
    ....
  14. ncbi request reprint Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice
    Pamela A Davol
    Cancer Immunotherapy Laboratory, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI 02908, USA
    Clin Prostate Cancer 3:112-21. 2004
    ..These findings suggest that Her2Bi-armed ATC therapy may be an effective, nontoxic, tumor-specific treatment for Her2-positive HRPC...
  15. ncbi request reprint How important is HER2/neu amplification and expression when selecting patients for HER2/neu-targeted therapies?
    Pamela A Davol
    Immunotherapy and Blood and Stem Cell Transplantation Programs, Adele R Decof Cancer Center, Roger Williams Medical Center, Providence, RI, USA
    Clin Breast Cancer 5:70-1. 2004
  16. ncbi request reprint Differentiation hotspots: the deterioration of hierarchy and stochasm
    Gerald A Colvin
    Department of Research, Roger Williams Medical Center, Providence, RI 02908, USA
    Blood Cells Mol Dis 32:34-41. 2004
    ..This data inaugurates the end of a pure stochastic model. This work complements existing scientific work without discounting it and adds an additional dimension of complexity (or simplicity) to the process of hematopoiesis...
  17. pmc Targeting human CD34+ hematopoietic stem cells with anti-CD45 x anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction
    Ting C Zhao
    Dept of Pediatrics, Women and Infants Hospital, Providence, RI 02905, USA
    J Appl Physiol 104:1793-800. 2008
    ..These results suggest that peripheral administration of armed CD34(+) HSC results in localization of CD34(+) HSC to injured myocardium and restores myocardial function...
  18. ncbi request reprint Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006
    ..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...
  19. ncbi request reprint Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model
    Lifen Ren-Heidenreich
    Molecular Immunology Laboratory, Adele R Decof Cancer Center, Roger Williams Hospital, Providence, Rhode Island 02908, USA
    Cancer 100:1095-103. 2004
    ....

Research Grants2

  1. Breast Cancer Treatment with Antibody Targeted T Cells
    Lawrence Lum; Fiscal Year: 2009
    ..Sequential Immune function tests on the blood and tumor sites will be performed to monitor immune responses (Aim 2) and to develop clinical correlates (Aim 3). ..
  2. Breast Cancer Treatment with Antibody Targeted T Cells
    Lawrence Lum; Fiscal Year: 2006
    ..The studies will provide immunologic insights as to whether armed ATC can alter the immune systems of patients with both HER2+. ..